Foundation Medicine buying Saga Dx and its MRD test for $595M
Nearly a year after the first U.S. commercial launch of the multicancer molecular residual disease (MRD) detection platform…
Roche builds MRD testing arsenal in $595m Saga Diagnostics buyout
Roche has agreed to acquire molecular residual disease (MRD) specialist, Saga Diagnostics and its platform in a $595m…